BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 22180425)

  • 1. Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning.
    Konopacki J; Porcher R; Robin M; Bieri S; Cayuela JM; Larghero J; Xhaard A; Andreoli AL; Dhedin N; Petropoulou A; Rodriguez-Otero P; Ribaud P; Moins-Teisserenc H; Carmagnat M; Toubert A; Chalandon Y; Socie G; Peffault de Latour R
    Haematologica; 2012 May; 97(5):710-6. PubMed ID: 22180425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.
    Peinemann F; Bartel C; Grouven U
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006407. PubMed ID: 23881658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.
    Bacigalupo A; Socie' G; Lanino E; Prete A; Locatelli F; Locasciulli A; Cesaro S; Shimoni A; Marsh J; Brune M; Van Lint MT; Oneto R; Passweg J;
    Haematologica; 2010 Jun; 95(6):976-82. PubMed ID: 20494932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
    Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
    Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
    Kang HJ; Shin HY; Park JE; Chung NG; Cho B; Kim HK; Kim SY; Lee YH; Lim YT; Yoo KH; Sung KW; Koo HH; Im HJ; Seo JJ; Park SK; Ahn HS;
    Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.
    Zhang Y; Liu L; Si Y; Miao M; Qiu H; Tang X; Han Y; Fu C; Jin Z; Chen S; Sun A; Wu D
    Hematology; 2021 Dec; 26(1):741-750. PubMed ID: 34555301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up.
    Kahl C; Leisenring W; Deeg HJ; Chauncey TR; Flowers ME; Martin PJ; Sanders JE; Storb R
    Br J Haematol; 2005 Sep; 130(5):747-51. PubMed ID: 16115132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
    Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
    Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen.
    Behfar M; Koochakzadeh L; Yazdanian N; Salajegheh P; Rostami T; Khodayari-Namini N; Ghavamzadeh A; Hamidieh AA
    Turk J Pediatr; 2019; 61(3):407-412. PubMed ID: 31916719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan.
    Chaudhry QUN; Iftikhar R; Satti TM; Mahmood SK; Ghafoor T; Shamshad GU; Farhan M; Shahbaz N; Khan MA; Khattak TA; Rehman J; Humayun S; Satti HS; Anwer F; Ahmed P
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2375-2382. PubMed ID: 31394274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow transplantation in children with severe aplastic anemia using a conditioning regimen containing 3 Gy of total body irradiation, cyclophosphamide with or without antithymocyte globulin.
    Inagaki J; Nagatoshi Y; Kawano Y; Saito Y; Takahashi D; Nagayama J; Shinkoda Y; Hirata H; Okamura J
    Pediatr Transplant; 2007 Mar; 11(2):180-6. PubMed ID: 17300498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia.
    Arcuri LJ; Nabhan SK; Cunha R; Nichele S; Ribeiro AAF; Fernandes JF; Daudt LE; Rodrigues ALM; Arrais-Rodrigues C; Seber A; Atta EH; de Oliveira JSR; Funke VAM; Loth G; Junior LGD; Paz A; Calixto RF; Gomes AA; Araujo CES; Colturato V; Simoes BP; Hamerschlak N; Flowers ME; Pasquini R; Rocha V; Bonfim C
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2311-2317. PubMed ID: 32949751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second haploidentical bone marrow transplantation with antithymocyte antibody-containing conditioning regimen for graft failure in eight patients with severe aplastic anemia.
    Zhang C; Hou Y; Yang Y; Zhang J; Zheng X; Yan J
    Sci Rep; 2024 Jan; 14(1):2293. PubMed ID: 38280947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treosulfan, cyclophosphamide and antithymocyte globulin for allogeneic hematopoietic cell transplantation in acquired severe aplastic anemia.
    Giebel S; Wojnar J; Krawczyk-Kulis M; Markiewicz M; Wylezoł I; Seweryn M; Holowiecka-Goral A; Holowiecki J
    Ann Transplant; 2006; 11(2):23-7; discussion 32-43. PubMed ID: 17494286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia.
    Chen X; Wei J; Huang Y; He Y; Yang D; Zhang R; Jiang E; Ma Q; Zhai W; Yao J; Zhang G; Feng S; Han M
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):86-90. PubMed ID: 29032265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.
    Pantin J; Tian X; Shah AA; Kurlander R; Ramos C; Cook L; Khuu H; Stroncek D; Leitman S; Barrett J; Donohue T; Young NS; Geller N; Childs RW
    Am J Hematol; 2013 Oct; 88(10):874-82. PubMed ID: 23813900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.